Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10825061 | 0.82 | ALDH1A1 (0.41) | PTPN22CYP1A2ERN1POLBHSD17B10 | |
| SCHEMBL20529660 | 0.79 | PTPN22 (0.54) | PTPN22CYP1A2ERN1POLBHSD17B10 | |
| SCHEMBL8204899 | 0.79 | PTPN22 (0.54) | PTPN22CYP1A2ERN1POLBHSD17B10 | |
| SCHEMBL1855575 | 0.79 | ESR1 (0.54) | PTPN22CYP1A2ERN1POLBHSD17B10 | |
| SCHEMBL30393017 | 0.79 | PTPN22 (0.54) | PTPN22CYP1A2ERN1POLBHSD17B10 | |
| Benzene SCHEMBL21836124 | 0.78 | PTPN22 (0.52) | PTPN22CYP1A2ERN1POLBHSD17B10 | |
| SCHEMBL3441131 | 0.77 | ALDH1A1 (0.46) | PTPN22CYP1A2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL28497134 | 0.76 | PTPN22 (0.50) | PTPN22CYP1A2ERN1POLBHSD17B10 | |
| SCHEMBL9819737 | 0.75 | ALDH1A1 (0.44) | PTPN22CYP1A2POLBHSD17B10ALDH1A1 | |
| SCHEMBL3246612 | 0.75 | ALDH1A1 (0.46) | PTPN22CYP1A2HSD17B10IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864017-B2 | Method of preparing lithium complex salts for use in electrochemical cells | MERCK PATENT GMBH (DE) | 2005-03-08 | — | — | US | claimed |
| US-20040091785-A1 | Method of preparing lithium complex salts for use in electrochemical cells | LEONOV ANDREI (DE) | 2004-05-13 | — | — | US | claimed |
| US-6582849-B1 | Stable (CF3)2N— salts and process for preparing them | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2003-06-24 | — | — | US | claimed |
| US-20030028023-A1 | Method of preparing lithium complex salts for use in electrochemical cells | LEONOV ANDREI (DE) | 2003-02-06 | — | — | US | claimed |
| US-6441216-B1 | CHEMICAL INTERMEDIATES; ELECTROLYTES | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-08-27 | — | — | US | claimed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | claimed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| EP-0015436-B1 | PROCESS FOR THE STEREOSPECIFIC PREPARATION OF COMPOUNDS OF THE VITAMIN K1- AND K2-SERIES, AS WELL AS NEW STARTING MATERIALS FOR THE PROCESS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-02-03 | — | — | EP | claimed |
| US-20210325783-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING RESIST PATTERN, METHOD FOR MANUFACTURING PLATED MOLDED ARTICLE, AND SEMICONDUCTOR APPARATUS | JSR CORPORATION (JP) | 2021-10-21 | — | — | US | disclosed |
| US-20210311391-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING RESIST PATTERN, METHOD FOR MANUFACTURING PLATED FORMED BODY, AND SEMICONDUCTOR DEVICE | JSR CORPORATION (JP) | 2021-10-07 | — | — | US | disclosed |
| WO-2020039755-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING RESIST PATTERN, METHOD FOR MANUFACTURING PLATED FORMED BODY, AND SEMICONDUCTOR DEVICE | JSR株式会社 | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039717-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING RESIST PATTERN, METHOD FOR MANUFACTURING PLATED MOLDED ARTICLE, AND SEMICONDUCTOR APPARATUS | JSR株式会社 | 2020-02-27 | — | — | WO | disclosed |
| US-20100298225-A1 | PEPTIDE GAP JUNCTION MODULATORS | ZEALAND PHARMA A/S (DK) | 2010-11-25 | — | — | US | disclosed |
| EP-2212343-A2 | PEPTIDE GAP JUNCTION MODULATORS | Zealand Pharma A/S (DK) | 2010-08-04 | — | — | EP | disclosed |
| US-RE29164-E | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
| US-4013648-A | BETA-LACTAM ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-4012383-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1977-03-15 | — | — | US | disclosed |
| US-4011216-A | Δ2,3-0-2-Isocephem-4-carboxylic acid and derivatives thereof as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1977-03-08 | — | — | US | disclosed |
| US-3985740-A | THERAPEUTIC AND ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3946000-A | BACTERICIDES, POULTRY, ANIMALS | BRISTOL-MYERS COMPANY (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298225-A1 | PEPTIDE GAP JUNCTION MODULATORS | GJA1, GJB2, GAP43 | PTPN22 1214/4885CYP1A2 4863/4885ERN1 3526/4885 |
| US-20030028023-A1 | Method of preparing lithium complex salts for use in electrochemical cells | CA3, MCU, CACNA2D3 | PTPN22 1501/4885CYP1A2 2582/4885ERN1 1572/4885 |
| US-20040091785-A1 | Method of preparing lithium complex salts for use in electrochemical cells | CA3, MCU, CACNA2D3 | PTPN22 1501/4885CYP1A2 2582/4885ERN1 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.